君实生物 · Junshi Biosciences
← News archive

· Clinical research

First patient dosed in Phase 3 liver cancer trial of JS207 and JS007

Junshi announced that the first patient had received treatment in a Phase 3 trial evaluating JS207 with JS007 as a first-line treatment for advanced hepatocellular carcinoma.

The study compares the investigational combination with toripalimab plus bevacizumab. The trial is registered as NCT07823348.

Read the full company release